44 results about "Lacidipine" patented technology

The invention provides lacidipine tablets and a preparation method thereof. The lacidipine tablets comprise 1-4% of lacidipine, 14-32% of hydroxypropyl cellulose or microcrystalline cellulose, 1-3% ofpoloxamer or sodium dodecyl sulfate or povidone or copovidone, 0.25-2% of magnesium stearate and the balance of lactose by weight percent, and the preparation method comprises the following steps ofevenly mixing raw material of the lacidipine with the lactose according to the weight ratio of 1:1 after ultra-fine smashing, further evenly mixing the mixture with the balance of the lactose and thehydroxypropyl cellulose or the microcrystalline cellulose, adding a water solution bonding agent prepared by the poloxamer or the odium dodecyl sulfate or the povidone or the copovidone, preparing appropriate soft materials, passing a 18-mesh sieve for granulation, drying at the temperature of 40-60 DEG C, passing a 16-mesh sieve for size stabilization, adding the magnesium stearate, evenly mixingand pressing tablets, thereby preparing products. The method can effectively improve the dissolution of the lacidipine tablets and lead the evenness index to achieve the more ideal value. The methodcan further improve the bioavailability of the lacidipine tablets and has the advantages of fast absorption, convenient administration and significant efficacy.

The invention relates to a process for preparing pharmaceutical preparation of Lacidipine, wherein the preparation prepared through the method has good dissolving property.

The invention provides a pharmaceutical composition which comprises calcium channel blockers of a medicinal dose, angiotensin II receptor antagonists of a medicinal dose, one or more of B vitamins of a medicinal dose and pharmaceutically acceptable carriers, wherein the calcium channel blockers are selected from amlodipine, felodipine, israbipine, nicardipine, nifedipine, nisoldipine, nitrendipine, lacidipine, diltiazem or verapamil; the angiotensin II receptor antagonists are selected from candesartan, telmisartan, losartan, valsartan, irbesartan, eprosartan, tasosartan or olmesartan; and the B vitamins are selected from one or more of vitamin B6, vitamin B12, folic acid and calcium leucovorin. The pharmaceutical composition of the invention can improve the curative effect of the hypotensor, enhance the target organ protecting action of the hypotensor, and reduce the morbidity of complications of angina, myocardial infarction and the like.

The invention relates to a pharmaceutical composition containing a calcium channel blocker (CCB) or the mixture thereof, an angiotonin 3II receptor blocker (ARB) or the mixture thereof, statins or the mixture thereof and a pharmaceutically acceptable carrier, wherein the CCB is selected from l-amlodipine, amlodipine, lacidipine, nitrendipine or the mixture thereof; the angiotonin II receptor blocker is selected from telmisartan, losartan, irbesartan, candesartan or the mixture thereof; and the statins are selected from atorvastatin, simvastatin, ruishufatadine, fluvastatin or the mixture thereof. The pharmaceutical composition is used for treating various high blood pressures and preventing or treating cardiovascular and cerebrovascular diseases relevant to the hypertension, reduces the disease rate and/or mortality rate of the cardiovascular and cerebrovascular diseases and also improves the adaptability for a sufferer taking medicine.

The invention belongs to the technical field of medicines and relates to lacidipine self-microemulsifying soft capsules and a preparation method thereof. The lacidipine self-microemulsifying soft capsules is uniform transparent solution prepared from an oil phase, an emulsifier and an auxiliary emulsifier, wherein under the conditions of an ambient temperature and mild stirring, the lacidipine self-microemulsifying soft capsules spontaneously emulsify to form emulsion droplet smaller than 500 nanometers; the ratio of the lacidipine to the auxiliary emulsifier to the emulsifier to the oil phase is 1:1-30:1-60:0.5-10 or 1: 1-30:1-30:0.5-10; a water soluble macromoleclar polymer can be added for prolonging the maintenance time of the saturated state of the solution of the medicament; and an antioxygen can be added for improving the chemical stability of the preparation. In the invention, the biological utilization rate of oral lacidipine is improved; and the cost is low, and the process is simple.

A method and composition are provided for the treatment of an anorectal disorder and for controlling the pain associated therewith. The method comprises administering to a subject in need of such treatment therapeutically effective amounts of a calcium channel blocker either alone or together with a nitric oxide donor. Amlodipine, anipamil, barnidipine, benidipine, bepridil, darodipine, diltiazem, efonidipine, felodipine, isradipine, lacidipine, lercanidipine, lidoflazine, manidipine, mepirodipine, nicardipine, nifedipine, niludipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, perhexiline, tiapamil, verapamil and pharmaceutically acceptable salts thereof, are suitable calcium channel blockers.

The invention discloses a lacidipine dispersible tablet and a preparation method thereof. A solid dispersion is prepared by adopting lacidipine as a medicinal active component and polyvinylpyrrolidone as a carrier material through a spray drying technology, and the solid dispersion is processed to prepare the dispersible tablet. The preparation of the solid dispersion from lacidipine and a proper amount of polyvinylpyrrolidone increases the solubility and dissolve-out speed of a medicine, promotes the absorption of the medicine in bodies and improves the bioavailability of the medicine. The preparation of the dispersible tablet from the solid dispersion enhances the medicine administration compliance of a patient.

The invention discloses a lacidipine sustained-release preparation and a preparation process thereof. The lacidipine sustained-release preparation comprises an effective dose of lacidipine or a physiologically acceptable salt of the lacidipine and a pharmaceutically acceptable medicinal auxiliary material. The lacidipine sustained-release pharmaceutical preparation prepared by the preparation process can make medicaments released smoothly in vivo to ensure the smooth of the blood concentration in vivo, thereby ensuring that the effective blood concentration in vivo of a patient during medication is smooth, and fundamentally improving the safety and the effectiveness of the medicaments.

The present invention relates to a kind of pharmaceutical composition, it comprises telmisartan salt and calcium ion antagonist or its pharmaceutically acceptable salt and pharmaceutically acceptable carrier; Described telmisartan salt is selected from telmisartan Sodium salt, potassium salt, calcium salt, magnesium salt or amine salt of sartan, described calcium ion antagonist is selected from amlodipine, lacidipine, cilnidipine, lercanidipine, nisoldipine, nica Dipine, azedipine, barnidipine, manidipine, benidipine, verapamil, diltiazem, or a pharmaceutically acceptable salt thereof. The composition is used for preventing, delaying progress or treating patients with hypertension, angina pectoris, atherosclerosis, stroke, cardiac insufficiency, dyslipidemia, diabetes, renal function damage or hypertension accompanied by Alzheimer's disease, reducing Reduce the morbidity and/or mortality of cardiovascular and cerebrovascular diseases, reduce adverse drug reactions, and improve patients' compliance with medication.

A process for preparing lacidipine, comprising reacting a t-butoxy carbonyl methyl aryl phosphonium halide with o-phthalaldehyde, and further reacting a product comprising (E)-3-(2-formylphenyl)-2-propenoic acid, 1,1-dimethyl ethyl ester, without isolation, with ethyl-3-amino crotonate.

The invention belongs to the technical field of medicines, relates to a lacidipine solid dispersion and a preparation method thereof, and in particular relates to a lacidipine ternary solid dispersionand a preparation method thereof. The ternary solid dispersion comprises lacidipine, a crystal nucleus inhibitor and a dissolution promoter, wherein the crystal nucleus inhibitor is a water-soluble high polymer material, and the dissolution promoter is an anionic polymer. The crystal nucleus inhibitor can inhibit a drug from forming a crystal nucleus by effects of forming hydrogen bonds with thedrug and the like, so that the drug can maintain a supersaturated state for a long time. The dissolution promoter can stabilize crystal nuclei already appearing in a system and prevent the crystal nuclei from further growing. Meanwhile, the dissolution promoter has high water solubility, so that the release rate of lacidipine under a non-leaking condition can be further increased under combined action of the crystal nucleus inhibitor and the dissolution promoter. The system can significantly improve the dissolution rate and bioavailability of lacidipine.

Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing hypertension and complications in patients with diabetes and/or metabolic syndrome. More particularly, aspects of the present invention are related to using a combination of cicletanine and lacidipine (a preferred calcium antagonist) for treating and/or preventing hypertension and complications in patients with diabetes and/or metabolic syndrome.

The invention provides a method utilizing extension primers with different molecular weights at different SNP (single nucleotide polymorphism) sites to detect multiple sites related to metabolism of an antihypertensive drug lacidipine by MALDI-TOF-MS (matrix-assisted laser desorption ionization time-of-flight mass spectrometry) and guide medication of lacidipine finally as well as a kit. The method comprises steps as follows: designing multiple amplification primers and extension primers respectively according to six target SNP sites to be detected; preparing a multi-amplification primer reaction system and an extension reaction system; performing amplification and single-base extension reactions on the six target SNP sites by multiple primers simultaneously respectively; performing time-of-flight mass spectrometry on products obtained after the single-base extension reaction, identifying genetypes of SNPs related to different drug metabolisms according to products, represented by massspectrum peaks, of extension primers with different molecular weights, and guiding the medication of the antihypertensive drug lacidipine. Meanwhile, the invention provides a detection kit utilizingthe method. The SNP sites related to metabolism of six antihypertensive drug lacidipine can be detected simultaneously, and the method has the advantages of low cost, no need of probe synthesis, low time consumption, simple and convenient result analysis and quite wide application field.

The invention provides a mass spectrography method for differentiation of individualized medication of lacidipine through a primer composition. According to different single nucleotide polymorphism (SNP) sites having extension primers with different molecular weights, through matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS), a plurality of sites pertinentto metabolism of a hypertension reducing medicine namely lacidipine can be detected at the same time, and finally the mass spectrography method for differentiation of individualized medication of lacidipine through the primer composition is obtained. The method comprises the steps of: according to 6 target SNP sites to be detected, separately designing multiplex amplification primers and an extension primer; compounding a multiplex amplification primer reaction system and an extension primer reaction system; in the reaction systems, performing an amplification reaction and a single-base extension reaction on the 6 target SNP sites at the same time with multiple sets of primers; and performing time-of-flight mass spectrometric analysis on products after the single-base extension reaction,identifying the genotypes of different drug metabolism relevant SNPs according to extension primer products with different molecular weights and represented by mass spectrum peaks, and guiding the medication of the hypertension reducing medicine namely the lacidipine. The method disclosed by the invention can detect 6 metabolism pertinent SNP sites of the hypertension reducing medicine namely thelacidipine at the same time, and has the advantages of being low in cost, free from probe synthesis, short in time consumption, simple and convenient in result analysis, and extremely broad in application field.

The invention belongs to the technical field of medicines and particularly relates to a lacidipine containing pharmaceutical composition for treating hypertension and a preparation method thereof. The lacidipine containing pharmaceutical composition for treating the hypertension, provided by the invention, is prepared from the following raw pharmaceutical materials in parts by weight: 3-5 parts of lacidipine, 2,000-4,000 parts of Mesona chinensis, 2,000-4,000 parts of Maesa indica, 2,000-4,000 parts of Eurya japonica, 2,000-4,000 parts of acanthopanax brachypus and 2,000-4,000 parts of Bulbopyllum psychoon. According to the lacidipine containing pharmaceutical composition for treating the hypertension and the preparation method thereof, the traditional Chinese medicines and the lacidipine are combined, so that common adverse reactions of the lacidipine can be avoided, and the treatment effect on the hypertension is improved.

The invention discloses a preparation method of a lacidipine composition. The preparation method is characterized by comprising the following steps: (1) dispersing lacidipine in molten poloxamer 188; (2) cooling and solidifying the product obtained in the step (1), and performing low-temperature crushing and sieving to obtain lacidipine solid dispersion powder; (3) mixing the mixture obtained in the step (2), polyvinylpyrrolidone (PVP) K30, cross-linked povidone and lactose, and carrying out dry granulation; and (4) uniformly mixing the mixture obtained in the step (3) with a proper amount of magnesium stearate and tabletting. According to the method, the content uniformity of the lacidipine preparation can be ensured, and the dissolution rate of the lacidipine preparation is improved, so that the bioavailability of the lacidipine is improved.

The invention provides application of lacidipine to preparing medicines for treating arenavirus infection, and belongs to the field of medicines. The application has the advantages that invasion of arenavirus into host cells can be effectively inhibited by the lacidipine in non-toxicity ranges, and accordingly virus infection due to the arenavirus can be effectively prevented and treated; the lacidipine is excellent in safety, further can be developed to obtain the medicines for treating or preventing the arenavirus infection and has a broad application prospect; the lacidipine further can be applied to preparing medicines for treating virus infection mediated by arenavirus envelope glycoprotein compounds and can act on the arenavirus envelope glycoprotein compounds, and accordingly the virus infection mediated by the arenavirus envelope glycoprotein compounds can be effectively inhibited; all different types of virus infection mediated by the arenavirus envelope glycoprotein compounds can be effectively treated and prevented by the lacidipine.

The invention relates to a lacidipine dispersible tablet and a preparation method thereof. The lacidipine dispersible tablet provided by the invention comprises the following components in parts by weight: 1 part of lacidipine, 5-12 parts of adhesives, 25-35 parts of disintegrating agents and 5-10 parts of diluents. The preparation method of the lacidipine dispersible tablet comprises the following steps of: (1) mixing the lacidipine and the adhesives, adding absolute ethyl alcohol and heating and stirring to complete dissolution; and (2) adding the disintegrating agents to the mixture obtained in the step (1), uniformly mixing, sieving and drying by blowing. The lacidipine dispersible tablet provided by the invention has the advantages of reasonable components, short disintegrating time, rapid medicine dissolution, rapid absorption and capability of improving medicine bioavailability, and the preparation process of the lacidipine dispersible tablet is simple and easy for enforcement and capable of realizing scale production.

The invention provides a slow-release preparation of calcium antagonist and salt thereof and a preparation method thereof. The slow-release preparation comprises a slow-release phase which contains active pharmaceutical ingredients, the active pharmaceutical ingredients include 5-40mg of amlodipine or salt thereof calculated by amlodipine, 4-32mg of lacidipine or salt thereof calculated by lacidipine, 5-40mg of nisoldipine or salt thereof calculated by nisoldipine, 5-40mg of cilnidipine or salt thereof calculated by cilnidipine, 2-32mg of benidipine or salt thereof calculated by benidipine, 10-80mg of lercanidipine or salt thereof calculated by lercanidipine and 5-80mg of manidipine or salt thereof calculated by manidipine; in release media meeting sink conditions, higher than 90% of weight of the active pharmaceutical ingredients are released within a release period of 6-14h. The slow-release preparation is convenient to use, good in treatment effect, high in taking compliance, little in adverse reaction, quick in action, capable of maintaining stable and effective blood concentration for a long time, ingenious in design, simple in structure, high in stability and suitable for large-scale popularization and application.

The invention discloses a method for determining concentration of lacidipine in blood plasma by adopting liquid chromatography-tandem mass spectrometry, and belongs to the technical field of pharmaceutical analysis. The method for determining the concentration of lacidipine in human plasma by adopting the liquid chromatography-tandem mass spectrometry is established in the invention, after a plasma sample is treated through using a protein precipitation method, a Luna PFP chromatographic column is adopted for rapid gradient elution chromatographic separation, and detection is conducted throughusing a tandem quadrupole mass spectrometer. The ion reactions monitored by mass spectrometry are as follows: m/z473.5 to 354.3(lacidipine) and m/z481.4 to 362.3(lacidipin-13C8). By adopting the method disclosed by the invention, the rapid and sensitive detection of lacidipine in the blood plasma can be realized, and the method can be applied to the bioequivalence research of lacidipine imitationmedicines.